Cocrystal Pharma (COCP) Liabilities and Shareholders Equity (2010 - 2026)

Cocrystal Pharma (COCP) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 30.33% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $36.1 million (down 41.72% YoY), and the FY2025 full-year result was $9.7 million, down 27.82% from the prior year.
• Liabilities and Shareholders Equity retreated to $7.4 million in Q1 2026, from $9.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $75.4 million in Q1 2022 to a low of $7.4 million in Q1 2026.
• A 5-year average of $28.0 million and a median of $26.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 39.96% in 2022 and sank 60.58% in 2025, its largest moves.
• Tracing COCP's Liabilities and Shareholders Equity over 5 years: stood at $40.8 million in 2022, then fell by 23.46% to $31.3 million in 2023, then sank by 56.95% to $13.5 million in 2024, then declined by 27.82% to $9.7 million in 2025, then retreated by 23.54% to $7.4 million in 2026.
• Business Quant data shows COCP's Liabilities and Shareholders Equity at $7.4 million in Q1 2026, $9.7 million in Q4 2025, and $10.4 million in Q3 2025.